Quanterix to participate in Canaccord Genuity Capital Markets 46th Annual Growth Conference on August 11-12. Posted on August 6, 2026 BILLERICA, Mass. - August 6, 2026 - Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that senior management will participate in the Canaccord Genuity Capital Markets 46th Annual Growth Conference at the Intercontinental Hotel in Boston on August 11-12, 2026. Chief Executive Officer Everett Cunningham will engage in a fireside chat that will be webcast live on 1:00 pm ET on Wednesday, August 12th, during which he will provide an update on the Company and its strategic priorities. Chief Technology and Product Officer Michael Miller will join a panel discussion on Neurology Diagnostics at 2:00 pm ET the same day. The Company is also scheduling one-on-one investor meetings both August 11th and 12th at the event, which will include Mr. Cunningham, Chief Financial Officer Jason Faessler and Mr. Miller. Webcast information. The live webcast presentation can be accessed from the Investor Relations section of the Company's website at www.quanterix.com. A replay of the webcast will be available following the conference on the website. About Quanterix. Quanterix is a global leader in precision biomarker science, making biology measurable to deliver earlier insights and support breakthroughs in disease research, diagnostics, and drug development. Its Simoa(R) technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. Through the acquisition of Akoya Biosciences, Quanterix Spatial solutions deliver high-plex, quantitative protein analysis in tissue at single-cell resolution. Combined with Accelerator Laboratory services, Quanterix gives researchers the tools and expertise to translate discovery into precision diagnostics. Learn more at www.quanterix.com.

Quanterix (QTRX) to post earnings on Thursday. July 30, 2026 Key points. * Quanterix is scheduled to report Q2 2026 results after market close on Thursday, August 6. Analysts expect a loss of $0.25 per share and revenue of approximately $37.5 million. * In the prior quarter, Quanterix reported a loss of $0.39 per share, beating estimates for a $0.51 loss, while revenue of $35.9 million fell short of forecasts. * Analyst sentiment remains cautious: the stock has an average "Reduce" rating and a $4.00 price target, while shares recently traded at $3.38 and institutional investors own 86.48% of the company. * MarketBeat previews top five stocks to own in August. Quanterix (NASDAQ:QTRX - Get Free Report) is expected to be posting its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to post earnings of ($0.25) per share and revenue of $37.4620 million for the quarter. Parties can check the company's upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET. Quanterix (NASDAQ:QTRX - Get Free Report) last issued its earnings results on Wednesday, May 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.12. Quanterix had a negative net margin of 71.86% and a negative return on equity of 23.92%. The business had revenue of $35.90 million for the quarter, compared to analyst estimates of $36.84 million. Quanterix trading down 3.2%. NASDAQ QTRX opened at $3.38 on Thursday. Quanterix has a 12-month low of $2.39 and a 12-month high of $8.77. The company has a market cap of $159.23 million, a P/E ratio of -1.43 and a beta of 1.04. The company has a fifty day simple moving average of $3.57 and a 200 day simple moving average of $4.39. Institutional investors weigh in on Quanterix. Several hedge funds and other institutional investors have recently made changes to their positions in QTRX. Deutsche Bank AG boosted its position in shares of Quanterix by 6.5% during the fourth quarter. Deutsche Bank AG now owns 29,906 shares of the company's stock worth $190,000 after acquiring an additional 1,817 shares during the last quarter. Intech Investment Management LLC boosted its holdings in Quanterix by 13.4% during the 3rd quarter. Intech Investment Management LLC now owns 19,161 shares of the company's stock valued at $104,000 after acquiring an additional 2,268 shares during the period. Jane Street Group LLC grew its holdings in shares of Quanterix by 4.2% in the first quarter. Jane Street Group LLC now owns 58,313 shares of the company's stock worth $380,000 after purchasing an additional 2,366 shares during the last quarter. Rhumbline Advisers increased its position in shares of Quanterix by 7.2% during the second quarter. Rhumbline Advisers now owns 60,629 shares of the company's stock worth $403,000 after acquiring an additional 4,094 shares during the period. Finally, Caitong International Asset Management Co. Ltd bought a new stake in Quanterix during the 4th quarter valued at $27,000. Hedge funds and other institutional investors own 86.48% of the company's stock. Analysts set new price targets. QTRX has been the subject of a number of research analyst reports. Weiss Ratings downgraded shares of Quanterix from a "sell (d-)" rating to a "sell (e+)" rating in a report on Wednesday, May 13th. Canaccord Genuity Group decreased their target price on Quanterix from $8.00 to $4.00 and set a "hold" rating on the stock in a research note on Monday, April 20th. Wall Street Zen raised Quanterix from a "sell" rating to a "hold" rating in a research note on Saturday, May 9th. Finally, TD Cowen cut their price objective on shares of Quanterix from $7.00 to $4.00 and set a "hold" rating for the company in a research note on Thursday, May 7th. Two equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Reduce" and an average price target of $4.00. Discover more Stock Ratings Screener EV Market Analysis Space Stocks Report Quanterix company profile. Quanterix Corporation is a life sciences and diagnostics company specializing in ultra-sensitive digital immunoassay platforms. Its proprietary Single Molecule Array (Simoa) technology enables researchers to detect and quantify proteins, peptides and nucleic acids at femtomolar concentrations, offering sensitivity that surpasses traditional immunoassay methods. By translating single-molecule detection into routine laboratory workflows, Quanterix aims to accelerate biomarker discovery and the development of novel diagnostics and therapeutics. The company's core product portfolio includes the Simoa HD-1 and HD-X Analyzers, which automate high-throughput digital immunoassays for quantifying low-abundance biomarkers. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Quanterix, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quanterix wasn't on the list. While Quanterix currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys. Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain - combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

ALZpath, Abbott partner on predictive Alzheimer's test. BIOTECH: ALZ's Proprietary Antibody Basis of Blood Test July 22, 2026 CARLSBAD - More than 41 million cases of dementia - roughly three-quarters of all cases - go undiagnosed worldwide, including millions of cases of Alzheimer's disease across the U.S. Alzheimer's testing can be costly, cumbersome and painful, often requiring either a cerebrospinal fluid test that involves a spinal tap or positron emission tomography (PET) imaging involving the injection of a safe but radioactive tracer compound. That diagnostic standard is slowly changing in part because of companies like ALZpath, which launched a licensing partnership with global health care company Abbott (NYSE: ABT) last month for the use of its proprietary antibody in the development of an in-vitro test for Alzheimer's disease. "With Alzheimer's disease, the earlier you treat, the better the outcome," ALZpath CEO Mike Banville said. "So the goal ultimately is to diagnose and treat people before they have symptoms, because by the time you have symptoms, you can slow the disease but stopping it is extremely difficult." ALZpath is the developer of an engineered pTau217 antibody, which can detect minute traces of the protein phosphorylated tau 217 in a person's blood, a biomarker of early Alzheimer's development. - Advertisement - The company primarily licenses its pTau217 antibody to large in vitro diagnostic companies, which then incorporate the antibody into the development of their tests. "If you go to get blood work done, it's likely going to be run on one of four-to-six companies' machines behind the scenes," Banville said. "So we said, 'that's the way to get access faster.'" Plethora of partners. ALZpath has previously established licensing partnerships with the Switzerland-based multinational health care giant Roche, Beckman Coulter Diagnostics and Siemens Healthineers. With the addition of Abbott, some 80% of blood-based in vitro diagnostic testing is conducted on devices made by ALZpath partners. According to Banville, establishing those licensing partnerships has been increasingly frictionless each time. "They're looking at all their options to optimize the assay to be competitive in the market," he said. "I think as we get more partners on, it becomes more of a very mutual conversation that we want to partner together." ALZpath's initial partnerships were with diagnostics companies like Quanterix, Bio-Techne and Alamar Biosciences that focus mainly on research into the pathology of Alzheimer's rather than developing consumer tests for the disease. That trend began to shift this year, according to Banville, as pTau217 testing is in its first stage of clinical use to determine if patients that are suffering from memory loss or cognitive issues have Alzheimer's or another illness. Published studies. In a study published July 15 in the journal JAMA and presented at the Alzheimer's Association International Conference in London, researchers from the Mass General Brigham Neuroscience Institute posited that pTau217 diagnostic testing could eventually be integral in determining which otherwise healthy patients may develop Alzheimer's symptoms in the ensuing five-to-10 years. ALZpath supported a similar study published in December in the journal Nature using a pTau217 antibody assay developed by Quanterix. The study found that more than one-tenth of adults over age 70 may benefit from treatments to slow cognitive decline. In addition to developing a potential predictive test, researchers are investigating the potential of medications that could delay or prevent the onset of Alzheimer's symptoms. Federal regulators have approved a handful of drugs that treat the disease by clearing the amyloid plaques in the brain that form in the brains of Alzheimer's patients, but researchers are still trying to grasp a way to prevent the disease from the outset. "The inflection point is this shift now from all the research to starting to get into the clinical use, especially with the diagnostics given that you can do something about it. So it's a really exciting time; I don't say that just for ALZpath, I think ultimately for patients to be able to get an early diagnosis and have some actions they can take." FOUNDED: 2020 CEO: Mike Banville HEADQUARTERS: Carlsbad BUSINESS: Alzheimer's disease diagnostic testing WEBSITE: alzpath.bio CONTACT: [email protected] NOTABLE: ALZpath was awarded the Diagnostics Innovation of the Year in 2025 by the market intelligence organization BioTech Breakthrough. Eli is an award-winning reporter primarily covering the tech and life sciences industries. He previously worked as the San Diego City Hall reporter for the regional wire City News Service. He has also covered public health, transportation and state and local politics in the San Francisco Bay Area for Local News Matters, the nonprofit arm of the regional wire Bay City News Service, where he also oversaw the development and daily content management of the outlet's public health and COVID-19 news and resource webpage. He is also a contributing writer covering Minor League Baseball for the analysis and commentary website Baseball Prospectus. Eli is a graduate of San Francisco State University and a native of Northern California. -Advertisement-